Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-03
2007-04-03
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S009340
Reexamination Certificate
active
10381734
ABSTRACT:
The invention relates to cyclopeptides, the method of their preparation and their utilization as inhibitors or activators of angiogenesis.These cyclopeptides comprise the following peptide sequence:in-line-formulae description="In-line Formulae" end="lead"?-Arg-Ile-Lys-Pro-His-Gln-Gly-in-line-formulae description="In-line Formulae" end="tail"?They can be used in systems for inhibition of angiogenesis that comprises a support (1), to which the cyclopeptide is affixed by means of an organic spacer arm (3) that may be provided with a moiety (4) capable of being spliced by an enzyme system.
REFERENCES:
patent: 5849692 (1998-12-01), Jonczyk et al.
patent: 5939383 (1999-08-01), Remacle et al.
patent: 0 844 252 (1998-05-01), None
patent: 99 40947 (1999-08-01), None
patent: 00 53219 (2000-09-01), None
B. Ivanov et al.: “Synthesis and use of a new bromoacetyl-derivatized heterotrifunctional amino acid for conjugation of cyclic RGD-containing peptides derived from human bone sialoprotein” Bioconjugate Chemistry, vol. 6, pp. 269-277, 1995.
D. Delforge et al.: “Solid-phase synthesis of tailed cyclic peptides: the use of alpha-allyl-protected aspartic acid leads to aspartimide and tetramethylguanidium formation” Letter In Peptide Science, vol. 3, pp. 89-97, May 1, 1996.
S.A. Kates et al.: “Automated allyl cleavage for continuous-flow synthesis of cyclic and branched peptides” Analytical Biochemistry, vol. 212, pp. 303-310 1993.
LG Presta et al.: “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders” Cancer Res., vol. 57, No. 20, pp. 4593-4599, Oct. 1997.
N. Ortega et al.: “Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectivity triggers endothelial cells with an angiogenic phenotype” Am J Panthol, vol. 151, No. 5, pp. 1215-1224, Nov. 1997.
Yves A. Muller et al.: “The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding” Structure, vol. 5, NO. 10, pp. 1325-1338, Oct. 15, 1997.
Svitlana Chetyrkina et al.: “Synthesis of N-Fmoc-4-[(diethylphosphone)-2′, 2′-difluoro-1′-hydroxyethyl]phenylalanine, a novel phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides” Tetrahedron Letters vol. 41, pp. 1923-1926, 2000.
Roselyne Binetruy-Tournaire et al.: “Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis” The EMBO Journal, vol. 19, No. 7, pp. 1525-1533, 2000.
Martin Hagedorn et al.: “Target molecules for anti-angiogenic therapy: from basic research to clinical trials” Critical Reviews in Oncology/Hematology, vol. 34, pp. 89-110, 2000.
Christine Piossek et al.: “Vascular endothelial growth factor (VEGF) receptor II-derived peptides inihibit VEGF” The Journal of Biological Chemistry, vol. 274, No. 9, pp. 5612-5619 1999.
Frederic Jonca et al.: “Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor” The Journal of Biological Chemistry, vol. 272, No. 39, pp. 24203-24209, 1997.
Napoleone Ferrara et al.: “Clinical applications of angiogenic growth factors and their inhibitors” Nature Medicine, vol. 5, No. 12, pp. 1359-1364, Dec. 1999.
D. Scott Wilbur et al.: “Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers” Bioconjugate Chem., vol. 9, pp. 813-825, 1998.
Katherine D. McReynolds et al.: “Syntehsis of biotinylated glycoconjugates and their use in a novel ELISA for direct comparison of HIV-1 Gp120 recognition of GalCer and related carbohydrate analogues” Bioconjugate Chem., vol. 10, pp. 1021-1031, 1999.
Yasufumi Sato et al.: “Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement plasminogen activator synthesis, and DNA synthesis” The Journal of Cell Biology, vol. 107, pp. 1199-1205, Sep. 1988.
Oliver Seltz et al.: “HYCRON, an allylic anchor for high-efficiency solid phase synthesis of protected peptides and glycopeptides” J. Org. Chem., vol. 62, pp. 813-826, 1997.
Wayne J. Fairbrother et al.: “Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site” Biochemistry, vol. 37, pp. 17754-17764, 1998.
Bertrand Carboni et al.: “Aliphatic amino azides as key building blocks for efficient polyamine syntheses” J. Org. Chem., vol. 58, pp. 3736-3741 1993.
Haimanot Bekele et al.: “Improved synthesis of the Boc and Fmoc derivatives of 4-(4′-aminoethyl)-6-dibenzofuranpropionic acid: an unnatural amino acid that nucleates beta-sheet folding” J. Org. Chem., vol. 62, pp. 2259-2262, 1997.
Betz Natacha
Bikfalvi Andreas
Deleris Gerard
Commissariat a l''Energie Atomique
Gudibande Satyanarayana R.
Gupta Anish
Universite de Bordeaux I
Universite Victor Segalen Bordeaux 2
LandOfFree
Cyclic peptides, method for preparing and use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic peptides, method for preparing and use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptides, method for preparing and use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775194